Tanshinone IIA inhibits leukemia THP-1 cell growth by induction of apoptosis

被引:54
作者
Liu, Jia-Jun [1 ]
Zhang, Yong [2 ]
Lin, Dong-Jun [1 ]
Xiao, Ruo-Zhi [1 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Hematol, Guangzhou 510630, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Nucl Med, Guangzhou 510630, Guangdong, Peoples R China
关键词
tanshinone IIA; apoptosis; leukemia; DOWN-REGULATION; IN-VITRO; CANCER; EXPRESSION; DEATH; BCL-2; PATHWAYS; EXTRACT; DANSHEN;
D O I
10.3892/or_00000326
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tanshinone IIA, a diterpene quinone extracted from the traditional herbal medicine, Salvia miltiorrhiza Bunge, has been reported to have anti-tumor effects on a large variety of cancer cells. The present study was undertaken to investigate the in vitro antiproliferation and apoptosis inducing effects of Tanshinone IIA on leukemia THP-1 cell lines and its mechanisms of action. MTT assay was used to detect the cell growth inhibitory rate; cell apoptotic rate and the mitochondrial membrane potential (Delta psi m) were investigated by flow cytometry (FCM), apoptotic morphology was observed by Hoechst 33258 staining and DNA fragmentation analysis. The expression of caspase-3 and different apoptosis modulators were analyzed by Western blotting. The results revealed that Tanshinone IIA inhibited the growth of THP-1 cells and caused significant apoptosis, the suppression was both in time- and dose-dependent manner. After treatment by Tanshinone IIA for 48 h, the percentage of disruption of Delta psi m gradually increased in a dose-dependent manner along with marked changes of cell apoptosis. Western blotting showed cleavage of the caspase-3 zymogen protein (32-kDa) with the appearance of its 20-kDa subunit and a dose-dependent cleavage of PARP, with the appearance of 89-kDa fragment; The expression of Bcl-2 and survivin was down-regulated remarkably while Bax expression was up-regulated concurrently after the cells were treated with Tanshinone IIA for 48 h. We therefore conclude that Tanshinone IIA has significant growth inhibition effects on THP-1 cells by induction of apoptosis, and that Tanshinone IIA-induced apoptosis on THP-1 cells is mainly related to the disruption of Delta psi m and activation of caspase-3 as well as down-regulation of anti-apoptotic protein Bcl-2, survivin and up-regulation of pro-apoptotic protein Bax. The results indicate that Tanshinone IIA may serve as a potential anti-leukemia reagent.
引用
收藏
页码:1075 / 1081
页数:7
相关论文
共 32 条
[1]   Bone-marrow relapse in paediatric acute lymphoblastic leukaemia [J].
Bailey, L. Charles ;
Lange, Beverly J. ;
Rheingold, Susan R. ;
Bunin, Nancy J. .
LANCET ONCOLOGY, 2008, 9 (09) :873-883
[2]   Caspase activation [J].
Boatright, KM ;
Salvesen, GS .
PROTEASES AND THE REGULATION OF BIOLOGICAL PROCESSES, 2003, 70 :233-242
[3]   Botanical medicine and cancer: a review of the safety and efficacy [J].
Boon, H ;
Wong, J .
EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (12) :2485-2501
[4]   Interaction between warfarin and danshen (Salvia miltiorrhiza) [J].
Chan, TYK .
ANNALS OF PHARMACOTHERAPY, 2001, 35 (04) :501-504
[5]   Molecular mechanisms of inhibitory activities of tanshinones on lipopolysaccharide-induced nitric oxide generation in RAW 264.7 cells [J].
Choi, HS ;
Cho, DI ;
Choi, HK ;
Im, SY ;
Ryu, SY ;
Kim, KM .
ARCHIVES OF PHARMACAL RESEARCH, 2004, 27 (12) :1233-1237
[6]   Multiple intracranial tumors in Philadelphia chromosome positive acute lymphoblastic leukemia: Successful treatment following aggressive supportive care, early cranial radiation, high dose chemotherapy and imatinib [J].
Cuvelier, Geoff D. E. ;
Vitali, Aleksander M. ;
Ford, Jason C. ;
Dix, David B. .
PEDIATRIC BLOOD & CANCER, 2008, 51 (01) :135-137
[7]   Apoptosis pathways in cancer and cancer therapy [J].
Debatin, KM .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2004, 53 (03) :153-159
[8]   Caspases: Keys in the ignition of cell death [J].
Denault, JB ;
Salvesen, GS .
CHEMICAL REVIEWS, 2002, 102 (12) :4489-4499
[9]  
Giannetti L, 2004, ONCOL REP, V11, P401
[10]  
Kim R, 2005, ONCOL REP, V14, P595